The following is a summary of “Risks of adverse events with mirtazapine for adults with major depressive disorder: a ...
Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...
A compelling new study is building on a growing body of evidence showing a common exercise supplement used to build muscle ...
Mind Medicine (MindMed) has dosed the first subject in the Phase III Panorama study of a proprietary form of lysergide ...
(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet ...
The MM120 ODT Phase 3 clinical development program also includes the Voyage study for GAD and the Emerge study for major depressive disorder (MDD). The U.S. Food and Drug Administration has granted ...
Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.
NeuroStar is committed to advancing the body of scientific research and elevating mental health treatment through robust research and data-driven innovation,” stated Keith J. Sullivan, President and ...
Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.
One of the biggest names in adult entertainment, Emily Willis, has been left permanently disabled after checking into a Malibu rehab center for drug addiction treatment, ...